Novartis (NOVN) Q4 2024 earnings summary

Executive summary

• Achieved one of the strongest performances in company history in 2024, with net sales of $50.3B (+12% cc, +11% USD), core operating income up 22% (cc), and margin expansion to 38.7%, driven by key brands and innovation milestones.

• Exceeded full-year guidance, with robust top- and bottom-line growth, and expressed confidence in continued growth for 2025, supported by pipeline momentum and successful new launches.

• Completed transformation into a pure-play innovative medicines company, focusing on four core therapeutic areas and expanding in priority geographies.

• Advanced pipeline with key approvals and filings, including Kisqali, Scemblix, Fabhalta, and positive pivotal trial results for OAV101.

• Major portfolio changes included the Sandoz spin-off and significant acquisitions such as Kate Therapeutics, Mariana Oncology, and MorphoSys AG.

Financial highlights

• FY 2024 net sales: $50.3B (+12% cc, +11% USD); Q4 net sales: $13.2B (+16% cc, +15% USD).

• Core operating income: $19.5B (+22% cc, +19% USD); Q4 core operating income: $4.9B (+29% cc).

• Net income: $11.9B (+45% USD); core EPS: $7.81 (+24% cc, +21% USD); Q4 core EPS: $1.98 (+33% cc, +29% USD).

• Free cash flow reached $16.3B (+24% USD); Q4 free cash flow: $3.6B (+70% USD).

• Core margin expanded to 38.7% for FY (+3.3 pts); operating income margin reached 28.9% (+7.4pp).

Outlook and guidance

• 2025 guidance: mid- to high-single-digit net sales growth and high-single- to low-double-digit core operating income growth (cc).

• Assumes US generic entry for Entresto, Tasigna, and Promacta mid-2025; expects strong H1 growth, with softer H2 due to generics.

• Midterm guidance reaffirmed: 5%+ sales CAGR through 2029 and 40%+ core margin by 2027.

• Currency headwind expected: -2% to -3% on sales and core operating income if current rates persist.

• Core net financial result expenses expected around $1B; core tax rate expected at 16–16.5%.